Literature DB >> 9597042

The production of the Alzheimer amyloid precursor protein (APP) in extraneuronal tissue does not increase in old age.

E Niederwolfsgruber1, T L Schmitt, I Blasko, K Trieb, M M Steger, C Maczek, J Hager, K Bobak, E Steiner, B Grubeck-Loebenstein.   

Abstract

Alzheimer's disease (AD) is characterized by the cerebral deposition of beta-amyloid (A beta). A beta plaques also occur in the brains of healthy aged individuals, and A beta concentrations are increased in the cerebrospinal fluid (CSF) in old age. Based on results from an in vitro senescence model on human fibroblasts, it was proposed that the production of the beta-amyloid precursor protein (APP) was increased during aging. No information was available as to whether APP production was also augmented in aged humans. It was therefore the aim of the present study to analyze APP in connective tissue, skeletal muscle, peripheral blood mononuclear cells, and serum samples from young and aged healthy individuals. APP production was assessed by Northern and Western blotting. The expression of the different APP isoforms was studied by reverse transcription-polymerase chain reaction (RT-PCR) technique. The results demonstrate that APP messenger ribonucleic acid (mRNA) and protein concentrations were identical in blood and tissue samples from young and aged individuals and that there were no age-dependent changes in the APP isoform production pattern. Thus, our data strongly argue against the possibility of an altered production of APP during healthy aging and underline the point that in vitro aging models may not accurately reflect the in vivo situation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9597042     DOI: 10.1093/gerona/53a.3.b186

Source DB:  PubMed          Journal:  J Gerontol A Biol Sci Med Sci        ISSN: 1079-5006            Impact factor:   6.053


  4 in total

Review 1.  Amyloidosis in Retinal Neurodegenerative Diseases.

Authors:  Ambra Masuzzo; Virginie Dinet; Chelsea Cavanagh; Frederic Mascarelli; Slavica Krantic
Journal:  Front Neurol       Date:  2016-08-08       Impact factor: 4.003

Review 2.  Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges.

Authors:  Holger Cynis; Jeffrey L Frost; Helen Crehan; Cynthia A Lemere
Journal:  Mol Neurodegener       Date:  2016-06-30       Impact factor: 14.195

3.  Moderate blast exposure alters gene expression and levels of amyloid precursor protein.

Authors:  Jessica Gill; Ann Cashion; Nicole Osier; Lindsay Arcurio; Vida Motamedi; Kristine C Dell; Walter Carr; Hyung-Suk Kim; Sijung Yun; Peter Walker; Stephen Ahlers; Matthew LoPresti; Angela Yarnell
Journal:  Neurol Genet       Date:  2017-09-27

4.  Pyroglutamate-modified Aβ(3-42) affects aggregation kinetics of Aβ(1-42) by accelerating primary and secondary pathways.

Authors:  C Dammers; M Schwarten; A K Buell; D Willbold
Journal:  Chem Sci       Date:  2017-05-05       Impact factor: 9.825

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.